Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | SELL | P14151 | 1/20 | 0.44 |
| ▸ | SELP | P16109 | 1/20 | 0.44 |
| ▸ | SELE | P16581 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1494319 | 0.85 | SELL (0.52) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL27864186 | 0.83 | SELL (0.50) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL9064476 | 0.83 | LMNA (0.41) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL3060235 | 0.79 | SELL (0.46) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL7942520 | 0.79 | GABRA1 (0.61) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL18357201 | 0.79 | ACHE (0.59) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL4623974 | 0.79 | LMNA (0.56) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL7033501 | 0.77 | LMNA (0.45) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL27439431 | 0.77 | GABRA1 (0.65) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL12096306 | 0.76 | CA1 (0.42) | LMNATRPA1SLC6A2HTR2BCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105106301-A | Novel agents for the treatment of disorders connected to impaired neurotransmission | DSM IP ASSETS BV | 2015-12-02 | — | — | CN | disclosed |
| EP-2049132-B1 | NOVEL AGENTS FOR THE TREATMENT OF DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS BV (NL) | 2012-12-05 | — | — | EP | disclosed |
| US-20110237533-A1 | NOVEL POLYPHENOL COMPOUND | AJINOMOTO CO.,INC. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110070326-A1 | OREGANO EXTRACT AND ITS COMPONENTS FOR ENHANCING VIGILANCE | DSM IP ASSETS B.V. (NL) | 2011-03-24 | — | — | US | disclosed |
| US-20100074976-A1 | NOVEL AGENTS FOR THE TREATMENT OF DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS B.V. (NL) | 2010-03-25 | — | — | US | disclosed |
| CN-101500588-A | Novel agents for the treatment of disorders associated with impaired neurotransmission | DSM IP ASSETS BV (NL) | 2009-08-05 | — | — | CN | disclosed |
| EP-2049132-A1 | NOVEL AGENTS FOR THE TREATMENT OF DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSMIP Assets B.V. (NL) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008017484-A1 | NOVEL AGENTS FOR THE TREATMENT OF DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS B.V. (NL) | 2008-02-14 | — | — | WO | disclosed |
| EP-1467958-A1 | PROCESS FOR PREPARING 3,3',5,5',6,6'-HEXAALKYL-2,2'-BIPHENOLS, 3,3',4,4',5,5'-HEXAALKYL-2,2'-BIPHENOLS AND 3,3',4,4',5,5',6,6'-OCTAALKYL-2,2'-BIPHENOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003045883-A1 | PROCESS FOR PREPARING 3,3',5,5',6,6'-HEXAALKYL-2,2'-BIPHENOLS, 3,3',4,4',5,5'-HEXAALKYL-2,2'-BIPHENOLS AND 3,3',4,4',5,5',6,6'-OCTAALKYL-2,2'-BIPHENOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237533-A1 | NOVEL POLYPHENOL COMPOUND | PNLIP, LPL, LIPC | LMNA 2410/4885TRPA1 2583/4885SLC6A2 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.